Switzerland's MoonLake Q2 net loss narrows as expenses fall

MoonLake Immunotherapeutics

10/08/2026 12:11

Overview
Switzerland biopharma reported Q2 net loss as operating expenses declined from prior quarter
Company ended Q2 with $537 mln in cash and expects cash runway to mid-2028
Phase 3 IZAR-1 trial in psoriatic arthritis met all clinical endpoints at Week 16

Outlook
MoonLake expects cash runway to mid-2028
Company anticipates submitting BLA for sonelokimab in HS by end-Sep. 2026
MoonLake expects full IZAR-1 Phase 3 trial readout in H1 2027

Result Drivers
EXPENSES DROP - R&D costs were $50.2 mln from $54.5 mln in Q1, while general expenses drop to $11.4 mln from $15.5  mln in Q1

Company press release: ID:nGNE7TZg5X

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.84
 
Q2 Net Loss
 
$61.81 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for MoonLake Immunotherapeutics is $30.00, about 64.3% above its August 7 closing price of $18.26

Reuters Recommended Reads
Aug 7 - Soligenix Q2 net loss narrows as R&D expenses fall
Aug 10 - Veru Q3 net loss narrows on lower G&A expenses
Aug 7 - Rapid Micro Biosystems Q2 revenue beats; reaffirms 2026 revenue forecast

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)